Targeting RAB27A Enhances Pembrolizumab Sensitivity and Alleviates Immune Escape via Inactivation of the PI3K /Akt/ mTOR Pathway in Triple‐Negative Breast Cancer
Clinical and Experimental Pharmacology and Physiology · 2026
DOI: 10.1111/1440-1681.70159 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Pharmacology and Physiology, 2026. Verfasst von Tong Sha und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Thyroid Surgery, Xinjiang Medical University Affiliated Tumor Hospital, The Clinical Medical Research Center of Breast and Thyro…. Hauptthemen laut MEDLINE: TOR Serine-Threonine Kinases, Triple Negative Breast Neoplasms, Proto-Oncogene Proteins c-akt, rab27 GTP-Binding Proteins. Die Arbeit nennt 44 Literaturangaben. Gefördert von: National Natural Science Foundation of China, The "Tianshan Talents Cultivation Program" Technology and Innovation Leading Talents Project, The Graduate Research and Innovation Project of Xinjiang Uygur Autonomous Region.
Abstract (Originalsprache)
Ras‐related protein Rab‐27A (RAB27A) is involved in tumour progression and immune regulation. This study investigated its role in triple‐negative breast cancer (TNBC) progression, immune escape and responsiveness to immune checkpoint inhibitors. RAB27A expression was analysed in TNBC tissues and public datasets. Gain‐ and loss‐of‐function experiments were performed in TNBC cells. Peripheral blood mononuclear cell (PBMC)‐based tumour coculture systems and xenograft mouse models were used to evaluate antitumor immunity and therapeutic responses. RAB27A was upregulated in TNBC and correlated with chemotherapy resistance, advanced T stage, high Ki‐67 expression and CD8 + T‐cell infiltration. RAB27A overexpression activated PI3K/Akt/mTOR signalling and promoted tumour cell migration and invasion, whereas RAB27A silencing had the opposite effects. Combined RAB27A targeting and PI3K inhibition decreased PD‐L1 expression and cell viability while increasing HLA‐I expression and apoptosis; these effects were further enhanced by pembrolizumab. In PBMC coculture models, combination treatment promoted T‐cell proliferation and CD8 + T‐cell expansion while suppressing malignant phenotypes. In vivo, RAB27A knockdown inhibited tumour growth, reduced PI3K/Akt/mTOR activation and PD‐L1 expression and increased HLA‐I expression. Targeting RAB27A enhances antitumor immunity and pembrolizumab sensitivity by blocking the PI3K/Akt/mTOR axis, representing a potential strategy to overcome immune resistance in TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast Thyroid Surgery, Xinjiang Medical University Affiliated Tumor Hospital, The Clinical Medical Research Center of Breast and Thyroid Tumors in Xinjiang, Urumqi, China.
ORCID-Profile: Binlin Ma
Förderung
- National Natural Science Foundation of China
- The "Tianshan Talents Cultivation Program" Technology and Innovation Leading Talents Project
- The Graduate Research and Innovation Project of Xinjiang Uygur Autonomous Region
Zitieren
APA
Sha, T., Fan, J., Wang, X., & Ma, B. (2026). Targeting RAB27A Enhances Pembrolizumab Sensitivity and Alleviates Immune Escape via Inactivation of the PI3K /Akt/ mTOR Pathway in Triple‐Negative Breast Cancer. Clinical and Experimental Pharmacology and Physiology. https://doi.org/10.1111/1440-1681.70159
Vancouver
Sha T, Fan J, Wang X, Ma B. Targeting RAB27A Enhances Pembrolizumab Sensitivity and Alleviates Immune Escape via Inactivation of the PI3K /Akt/ mTOR Pathway in Triple‐Negative Breast Cancer. Clinical and Experimental Pharmacology and Physiology. 2026. doi:10.1111/1440-1681.70159
BibTeX
@article{Sha2026,
author = {Sha, Tong and Fan, Jingjing and Wang, Xiaoli and Ma, Binlin},
title = {Targeting RAB27A Enhances Pembrolizumab Sensitivity and Alleviates Immune Escape via Inactivation of the PI3K /Akt/ mTOR Pathway in Triple‐Negative Breast Cancer},
journal = {Clinical and Experimental Pharmacology and Physiology},
year = {2026},
doi = {10.1111/1440-1681.70159}
}
EUVIMED